←
NextPoint Therapeutics57 posts
NextPoint Therapeutics avatar

NextPoint Therapeutics

@NextPointTX

NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway.

◷ Joined November 2022▧ 54 Photos and videos
NextPoint Therapeutics avatar
NextPoint Therapeutics@NextPointTX·Nov 3

NextPoint Therapeutics' Vice President, Biology Matt Rausch will attend #SITC2026, Nov. 4–8. Our lead program, NPX372, is in Phase 1 development, with early data showing signs of T cell activation. Attending SITC? Connect with Matt to discuss our B7-H7 programs.

Post attachment
NextPoint Therapeutics avatar
NextPoint Therapeutics@NextPointTX·Oct 22

NextPoint CMO Leena Gandhi, MD, PhD, will attend #ESMO2026 in Madrid, October 23–27. We look forward to discussing our B7-H7-targeted pipeline, including T cell engagers, ADCs and checkpoint inhibitors, and connecting with the oncology community.

Post attachment
NextPoint Therapeutics avatar
NextPoint Therapeutics@NextPointTX·Oct 13

NextPoint Therapeutics CEO Ivan Cheung will attend the Goldman Sachs Healthcare Private Company Conference on October 19 in NYC. Attending? Connect with Ivan to learn more about our approach to developing novel cancer immunotherapies targeting B7-H7. #ImmunoOncology

Post attachment
NextPoint Therapeutics avatar
NextPoint Therapeutics@NextPointTX·Oct 8

NextPoint will participate in the Needham Private Biotech & MedTech Virtual 1×1 Forum, Oct. 13–14. CEO Ivan Cheung looks forward to connecting with investors and sharing updates on NextPoint. Interested in meeting with Ivan? Please reach out!

Post attachment
NextPoint Therapeutics avatar
NextPoint Therapeutics@NextPointTX·Sep 8

NextPoint CSO Tatiana Novobrantseva, Ph.D., will be speaking at the World Bispecific Summit with an Industry Leaders Panel, followed by a presentation on NextPoint’s approach to B7-H7 and the development of NPX372. Attending? Let's connect! #WorldBispecificSummit

Post attachment
NextPoint Therapeutics avatar
NextPoint Therapeutics@NextPointTX·Mar 12

Executive Director Matthew Rausch, PhD, is presenting a poster atSITC Spring Scientific meeting. The poster explores the biology of the B7-H7 pathway and its potential to enhance T-cell–mediated anti-tumor responses. Reach out if you want to connect! #SITC

Post attachment
NextPoint Therapeutics avatar
NextPoint Therapeutics@NextPointTX·Feb 10

In Scrip’s “What Does 2026 Hold for Biopharma?” outlook, Tatiana Novobrantseva, CSO of NextPoint Therapeutics, shares her view on where oncology differentiation is headed, novel targets, deep biology, and modality-agnostic precision. Read more: bit.ly/4qXtqz2

Post attachment
NextPoint Therapeutics avatar
NextPoint Therapeutics@NextPointTX·Feb 9

Clinical entry of NPX372, a first-in-class B7-H7–targeted T cell engager, following U.S. IND clearance. The first-in-human study pairs an IgG-like CD3 bispecific with biomarker-driven patient selection to enable rapid clinical readouts in solid tumors. bit.ly/4bPxSvf

Post attachment
NextPoint Therapeutics avatar
NextPoint Therapeutics@NextPointTX·Jan 29

A look at CEO Ivan Cheung presenting at the JP Morgan Conference. Ivan shared our precision oncology strategy across T cell engager, ADC and checkpoint inhibitor, grounded in B7-H7 science and biomarker-driven patient selection. Energized by conversations and year ahead.

Post attachment
NextPoint Therapeutics avatar
NextPoint Therapeutics@NextPointTX·Jan 23

Jamie Strand, Ph.D., VP of Technical Operations, will speak at the CMC Strategy Forum North America on Jan 26, sharing how protein engineering and CMC-driven cell-line development support consistent, manufacturable B7-H7 biologics ready for the clinic. #CASSS #CMCNA2026

Post attachment
NextPoint Therapeutics avatar
NextPoint Therapeutics@NextPointTX·Jan 5

Ivan Cheung, CEO of NextPoint Therapeutics, will present at the 2026 J.P. Morgan Healthcare Conference on Jan 15 at 8:30 am in San Francisco. NextPoint is advancing precision therapeutics across multiple modalities targeting B7-H7.  #JPM2026

Post attachment
NextPoint Therapeutics avatar
NextPoint Therapeutics@NextPointTX·23 Oct 2025

Data from NextPoint Therapeutics at #AACR-NCI-EORTC! NPX125, a B7-H7–targeting ADC, shows potent anti-tumor activity across solid tumor models. Reinforcing the promise of B7-H7 as a next-generation ADC target.

Post attachment
NextPoint Therapeutics avatar
NextPoint Therapeutics@NextPointTX·13 Oct 2025

Headed to AACR-NCI-EORTC! Sr. Scientist Emilien Loeuillard will present a poster on NPX125, our novel ADC targeting B7-H7, a molecule central to tumor immune escape and highly expressed in tumors.

Post attachment
NextPoint Therapeutics avatar
NextPoint Therapeutics@NextPointTX·3 Oct 2025

Join NextPoint Chief Scientific Officer Tatiana Novobrantseva and Director, Research and Development Melissa Hayes, at #SITC25 where they will be presenting the poster: TMIGD2 co-stimulation in a trispecific T cell engager elicits potent anti-tumor activity.

Post attachment
NextPoint Therapeutics avatar
NextPoint Therapeutics@NextPointTX·13 Aug 2025

Heading to the ADC Linker & Conjugation Summit? Catch NextPoint CSO Tatiana Novobrantseva, PhD, on Aug 20 as she shares unique attributes of NPX125, a DAR8 B7-H7 targeting ADC with a novel linker. Can't make it? Let's connect!

Post attachment